ArticleOphthalmology science2026
Intraocular Pressure-Lowering Therapy Slows Down Axial Elongation in Progressive High Myopia with Enhanced Choroidal Perfusion.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of intraocular pressure (IOP)-lowering medications in slowing down axial elongation among adults with progressive high myopia (PHM). Design: A retrospective longitudinal cohort study. Participants: Fifty eyes from 50 adults with PHM (axial elongation ≥0.1 mm/year prior to using IOP-lowering medications) who initiated IOP-lowering medications at Zhongshan Ophthalmic Center between December 2019 and May 2025. Methods: A comprehensive set of variables, including demographic data, ocular characteristics, and OCT angiography imaging were collected and analyzed. Main Outcome Measures: Change in the axial elongation rate before and after ≥12 months of IOP-lowering medication use. Results: Of the 1628 participants, 50 eyes from 50 eligible participants were finally analyzed. These participants had a mean age of 40.4 ± 10.7 years, with 72% being female; the mean number of IOP-lowering medications they used was 2.0 ± 0.3. After 12 months of follow-up, IOP decreased from 13.49 (2.50) to 12.03 (2.28) mmHg ( Conclusions: In this cohort, IOP-lowering therapy was associated with reduced axial elongation in adults with PHM, with concurrent modest enhancement of perfusion in DCP and CC. These findings support IOP-lowering therapy as a potential strategy to slow myopia progression in adults with PHM. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.